BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

Reuters

Sep 25

Sept 25 (Reuters) - Aclarion Inc ACON.O:

FIRST PATIENTS ENROLLED AT UHEALTH – UNIVERSITY OF MIAMI IN ACLARION’S PIVOTAL CLARITY TRIAL
ACLARION: ENROLLMENT REMAINS ON TRACK WITH INTERNAL INTERIM RESULTS EXPECTED IN Q2 2026

Source text: ID:nGNXbFXWHN

Further company coverage: ACON.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570685093"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570685093\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570685093?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570685093","market":"us","top_or_hot":-1,"title":"BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial</title></head><body><p><span>Sept 25 (Reuters)</span><span> - </span>Aclarion Inc <span>ACON.O</span>:</p><ul><li><p>FIRST PATIENTS ENROLLED AT UHEALTH – UNIVERSITY OF MIAMI IN ACLARION’S PIVOTAL CLARITY TRIAL</p></li><li><p>ACLARION: ENROLLMENT REMAINS ON TRACK WITH INTERNAL INTERIM RESULTS EXPECTED IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p>Source text: <span>ID:nGNXbFXWHN</span></p><p>Further company coverage: <span>ACON.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-25 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial</title></head><body><p><span>Sept 25 (Reuters)</span><span> - </span>Aclarion Inc <span>ACON.O</span>:</p><ul><li><p>FIRST PATIENTS ENROLLED AT UHEALTH – UNIVERSITY OF MIAMI IN ACLARION’S PIVOTAL CLARITY TRIAL</p></li><li><p>ACLARION: ENROLLMENT REMAINS ON TRACK WITH INTERNAL INTERIM RESULTS EXPECTED IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li></ul><p>Source text: <span>ID:nGNXbFXWHN</span></p><p>Further company coverage: <span>ACON.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACON","symbol_name":"ACLARION, INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nTUABY4KJY:1","article_id":"2570685093","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570685093","pubTimestamp":1758794649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY TrialSept 25 (Reuters) - Aclarion Inc ACON.O:FIRST PATIENTS ENROLLED AT UHEALTH – UNIVERSITY OF MIAMI IN AC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACON":"ACLARION, INC","ACONW":"Aclarion Equity Warrant Exp 1st Dec 2026 Warrant","BK4167":"医疗保健技术"},"translate_title":"简介-迈阿密大学UHealth首次招募患者参加Aclarion的关键CLARITY试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACON":0.9,"ACONW":0.9},"content_text":"BRIEF-First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY TrialSept 25 (Reuters) - Aclarion Inc ACON.O:FIRST PATIENTS ENROLLED AT UHEALTH – UNIVERSITY OF MIAMI IN ACLARION’S PIVOTAL CLARITY TRIALACLARION: ENROLLMENT REMAINS ON TRACK WITH INTERNAL INTERIM RESULTS EXPECTED IN Q2 2026Source text: ID:nGNXbFXWHNFurther company coverage: ACON.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}